4 th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond,May 12–14,2011,Budapest,Hungary

Hanefeld M , Koehler C , Hoffmann C , Wilhelm K , Kamke W , Gerstein H . Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. Diabet Med, 2010; 27:175–180.

Borg R , Kuenen JC , Carstensen B , Zheng H , Nathan DM , Heine RJ , Nerup J , Borch-Johnsen K , Witte DR . ADAG Study Group: HbA1_c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia, 2011; 54:69–72.

Muggeo M , Zoppini G , Bonora E , Brun E , Bonadonna RC , Moghetti P , Verlato G . Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care, 2000; 23:45–50.

Takao T , Ide T , Yanagisawa H , Kikuchi M , Kawazu S , Matsuyama Y . The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Res Clin Pract, 2010; 89:296–302.

International Diabetes Federation. Self-Monitoring of Blood Glucose in Non-Insulin-Treated Type 2 Diabetes. Brussels: International Diabetes Federation, 2009.

Polonsky WH , Fisher L , Schikman CH , Hinnen DA , Parkin CG , Jelsovsky Z , Petersen B , Schweitzer M , Wagner RS . Structured self-monitoring of blood glucose significantly reduces A1c levels in poorly controlled, noninsulin-treated type 2 diabetes—results from the Structured Testing Program Study. Diabetes Care, 2011; 34:262–267.

McManus RJ , Mant J , Bray EP , Holder R , Jones MI , Greenfield S , Kaambwa B , Banting M , Bryan S , Little P , Williams B , Hobbs FD . Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet, 2010; 376:163–172.

Hoffmann-La Roche. PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)NCT00643474.March 15, 2011ClinicalTrials.gov2011 May 23.

American Association of Diabetes Educators: Diabetes Education Fact Sheet. www.diabeteseducator.org/export/sites/aade/_resources/pdf/research/Diabetes_Education_Fact_Sheet_09-10.pdf. 2011 August 15.

Peyrot M , Rubin RR . Access to diabetes self-management education. Diabetes Educ, 2008; 34:90.

AbuDagga A , Resnick HE , Alwan M . Impact of blood pressure telemonitoring on hypertension outcomes: a literature review. Telemed J E Health, 2010; 16:830–838.

Polisena J , Tran K , Cimon K , Hutton B , McGill S , Palmer K . Home telehealth for diabetes management: a systematic review and meta-analysis. Diabetes Obes Metab, 2009; 11:913–930.

Leichter SB , Adkins RA , Bowman KL . Telemedical management of diabetic patients by computer versus traditional care: a controlled clinical trial [late breaking poster] Presented at General Poster Session II, American Diabetes Association. 71st Scientific Sessions: San Diego, CA, 2011.

Yaffe K , Blackwell T, MS , Kanaya AM , Davidowitz N , Barrett-Connor E , Krueger K . Diabetes, impaired fasting glucose and development of cognitive impairment in older women. Neurology, 2004; 63:658–663.

Yaffe K , Blackwell T , Whitmer RA , Krueger K , Barrett Connor E . Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Ageing, 2006; 10:293–295.

Traykov L , Boller F . Frontal lobes pathology, dementia. An appraisal of the contribution of Leonardo Bianchi. Ital J Neurol Sci, 1997; 18:129–134.

Boller F , Traykov L , Dao-Castellana MH , Fontaine-Dabernard A , Zilbovicius M , Rancurel G , Pappata S , Samson Y . Cognitive functioning in “diffuse” pathology. Role of prefrontal and limbic structures. Ann N Y Acad Sci, 1995; 769:23–39.

Segura B , Jurado MA , Freixenet N , Falcón C , Junqué C , Arboix A . Microstructural white matter changes in metabolic syndrome. A diffusion tensor imaging study. Neurology, 2009; 73:438–444.

Prochaska JO , DiClemente CC . The transtheoretical approach. Norcross JC , Goldfried MR . Handbook of Psychotherapy Integration, 2 ^nd. New York: Oxford University Press, 2005; 147–171.

Leventhal H , Meyer D , Nerenz D . The common sense representation of illness danger. Rachman S . Medical Psychology, II. New York: Pergamon Press, 1980; 7–30.

Bandura A . Social Foundations of Thought Action: A Social Cognitive Theory. Englewood Cliffs, NJ: Prentice-Hall, 1986.

Skinner TC , van der Ven N . Psychological group interventions in diabetes care. Snoek F , Skinner C . Psychology in Diabetes Care. Chichester, UK: John Wiley & Sons Ltd., 2004; 141–169.

Anderson RM . Patient empowerment and the traditional medical model: a case of irreconcilable differences? Diabetes Care, 1995; 18:412–425.

Holman H , Lorig K . Patients as partners in managing chronic disease. BMJ, 2000; 320:526–527.

Plack K , Herpertz S , Petrak F . Behavioural medicine interventions in diabetes. Curr Opin Psychiatry, 2010; 23:131–138.

Peyrot M , Rubin RR . Behavioral and psychosocial interventions in diabetes. Diabetes Care, 2007; 30:2433–2440.

Cramer JA , Pugh MJ . The influence of insulin usage on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care, 2005; 28:78–83.

Pound P , Britten N , Morgan M , Yardley L , Pope C , Daker-White G , Campbell R . Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med, 2005; 61:133–155.

Kerse N , Buetow S , Mainous AG 3rd , Young G , Coster G , Arroll B . Physician-patient relationship and medication compliance: a primary care investigation. Ann Fam Med, 2004; 2:455–461.

Haffner SM , Lehto S , Rönnemaa T , Pyörälä K , Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339:229–234.

Carnethon MR , Biggs ML , Barzilay J , Kuller LH , Mozaffarian D , Mukamal K , Smith NL , Siscovick D . Diabetes, coronary heart disease as risk factors for mortality in older adults. Am J Med, 2010; 123:556.e1–e9.

Bartnik M , Rydén L , Malmberg K , Ohrvik J , Pyörälä K , Standl E , Ferrari R , Simoons M , Soler-Soler J . Euro Heart Survey Investigators: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J, 2004; 25:1990–1997.

International Expert Committee. Nathan DM . International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care, 2009; 32:1327–1334.

Schnell O , Hoffmann U , Otter W , Heinemann L , Hunger-Battefeld W , Kulzer B , Klinge A , Lodwig V , Amann-Zalán I , Sturm D , Tschöpe D , Spitzer SG , Stumpf J , Lohmann T , Dörr R . Die “Silent Diabetes” Studie: Oraler Glukosetoleranztest vs. HbA1c zur Neudiagnose des Diabetes bei Patienten mit KHK-Verdacht [poster P132, 46] Presented at Poster Session A, 46th Annual Meeting of the German Diabetes Society DDG, June 1–4, 2011, Leipzig, Germany.

von Eckardstein A , Schulte H , Assmann G . Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab, 2000; 85:3101–3108.

Cholesterol Treatment Trialists' (CTT) Collaboration:. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet, 2010; 376:1670–1681.

The ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–1574. Erratum in N Engl J Med, 2010; 362:1748.

Sorrentino SA , Besler C , Rohrer L , Meyer M , Heinrich K , Bahlmann FH , Mueller M , Horváth T , Doerries C , Heinemann M , Flemmer S , Markowski A , Manes C , Bahr MJ , Haller H , von Eckardstein A , Drexler H , Landmesser U . Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation, 2010; 121:110–122.

Drew BG , Duffy SJ , Formosa MF , Natoli AK , Henstridge DC , Penfold SA , Thomas WG , Mukhamedova N , de Courten B , Forbes JM , Yap FY , Kaye DM , van Hall G , Febbraio MA , Kemp BE , Sviridov D , Steinberg GR , Kingwell BA . High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation, 2009; 119:2103–2111.

von Eckardstein A , Sibler RA . Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol, 2011; 22:26–32.

Khot UN , Khot MB , Bajzer CT , Sapp SK , Ohman EM , Brener SJ , Ellis SG , Lincoff AM , Topol EJ . Prevalence of conventional risk factors in patients with coronary heart disease. JAMA, 2003; 290:898–904.

Ridker PM , Danielson E , Fonseca FA , Genest J , Gotto AM Jr , Kastelein JJ , Koenig W , Libby P , Lorenzatti AJ , MacFadyen JG , Nordestgaard BG , Shepherd J , Willerson JT , Glynn RJ . JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359:2195–2207.

Pradhan AD , Everett BM , Cook NR , Rifai N , Ridker PM . Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA, 2009; 302:1186–1194.

Goldfine AB , Fonseca V , Jablonski KA , Pyle L , Staten MA , Shoelson SE . TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team: The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med, 2010; 152:346–357.

Blankenberg S , Zeller T , Saarela O , Havulinna AS , Kee F , Tunstall-Pedoe H , Kuulasmaa K , Yarnell J , Schnabel RB , Wild PS , Münzel TF , Lackner KJ , Tiret L , Evans A , Salomaa V . MORGAM Project: Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation, 2010; 121:2388–2397.

Salomaa V , Havulinna A , Saarela O , Zeller T , Jousilahti P , Jula A , Muenzel T , Aromaa A , Evans A , Kuulasmaa K , Blankenberg S . Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One, 2010; 5:e10100.

Yusuf S , Hawken S , Ounpuu S , Dans T , Avezum A , Lanas F , McQueen M , Budaj A , Pais P , Varigos J , Lisheng L . INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004; 364:937–952.

Turner RC , Millns H , Neil HAW , Stratton IM , Manley SE , Matthews DR , Holman RR . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ, 1998; 316:823–828.

Taylor AJ , Sullenberger LE , Lee HJ , Lee JK , Grace KA . Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 2004; 110:3512–3517.

Stein EA , Stroes ES , Steiner G , Buckley BM , Capponi AM , Burgess T , Niesor EJ , Kallend D , Kastelein JJ . Safety and tolerability of dalcetrapib. Am J Cardiol, 2009; 104:82–91.

Cannon CP , Shah S , Dansky HM , Davidson M , Brinton EA , Gotto AM , Stepanavage M , Liu SX , Gibbons P , Ashraf TB , Zafarino J , Mitchel Y , Barter P . DEFINE Investigators: Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med, 2010; 363:2406–2415.

Hofmann-La Roche. A study assessing the effect of RO4607381 on vascular function in patients with coronary heart disease (CHD) or CHD-risk equivalent patientsNCT00655538. ClinicalTrials.gov2011 May 23.

Hofmann-La Roche. A study of the effect of RO4607381 on atherosclerotic plaque in patients with coronary heart diseaseNCT00655473. ClinicalTrials.gov2011 May 23.

Hofmann-La Roche. A study of the effect of dalcetrapib on artherosclerotic disease in patients with coronary artery diseaseNCT01059682. ClinicalTrials.gov2011 May 23.

Plassmann H , O'Doherty J , Shiv B , Rangel A . Marketing actions can modulate neural representations of experienced pleasantness. Proc Natl Acad Sci U S A, 2008; 105:1050–1054.